Favorite this paper
How to cite this paper?
Abstract

Alemtuzumab, a high efficacy therapy (HET) for multiple sclerosis (MS) patients in Brazil's public healthcare system, is reserved for cases where natalizumab has failed or is contraindicated due to its effectiveness. Despite being relatively common, infusion-associated reactions (IAR) with alemtuzumab are mostly mild and manageable with pre-infusion protocols involving corticosteroids, antihistamines, and analgesics.

 

However, severe IARs can occur, posing risks to patients, yet data on clinical presentation and management remain limited. The objective of this study is to report three cases of serious adverse reactions linked to alemtuzumab infusion in MS patients. These patients were treated at two neuroimmunology clinics in São Paulo.

 

Inclusion criteria encompassed MS patients treated with alemtuzumab infusion without contraindications. All received 12 mg of intravenous alemtuzumab, premedicated with methylprednisolone, diphenhydramine, and acetaminophen. Nursing and medical staff were trained to manage adverse effects promptly.

 

Case 1 involved a 45-year-old female experiencing acute generalized pain, somnolence, dyspnea, and hypertensive crisis during her second infusion. Treatment was paused, and a new cycle of steroids and symptomatic drugs was initiated.

 

Case 2, a 35-year-old male, developed acute ataxia, hypertension, and fever within two hours of infusion on the third day. The infusion was paused, and a stroke protocol was enacted to rule out vascular complications.

 

Case 3, a 44-year-old female, presented with bilateral leg weakness and fever within two hours of infusion. Similar symptoms d during previous MS relapses were reported, yet both patients underwent a stroke protocol due to acute onset. Symptoms resolved with antipyretics.

 

Discussion suggests these IARs correspond to cytokine storm syndrome, involving release of TNF-alpha, IFN-Gamma, and IL-6, leading to fever, rash, dyspnea, and blood pressure fluctuations. Infusion-associated reactions, exceeding 90%, highlight the importance of healthcare providers being vigilant regarding potential side effects associated with alemtuzumab infusion in MS treatment.

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 HCFMUSP
  • 2 .
  • 3 Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
  • 4 University of São Paulo Faculty of Medicine Clinics Hospital
  • 5 Hospital do Servidor Estadual de São Paulo (IAMSPE)
  • 6 Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo; São Camilo Hospital
  • 7 Neurology Department - Hospital das Clínicas São Paulo University, Sao Paulo, Brazil
Track
  • 4. MS treatment
Keywords
Alemtuzumab
Infusion
Adverse Events